FDA grants priority review for Merck's KEYTRUDA combinations in bladder cancer
The U.S. Food and Drug Administration has granted priority review for two supplemental Biologics License Applications from Merck (NYSE: MRK) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)